Completed

Early Vitrectomy vs. Conventional Management in Severe Diabetic Retinopathy

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Cardiovascular Diseases+12

+ Diabetes Mellitus

+ Diabetic Angiopathies

From 18 to 70 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 3
Interventional
Study Start: October 1976
See protocol details

Summary

Principal SponsorNational Eye Institute (NEI)
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: October 1, 1976

Actual date on which the first participant was enrolled.

This study is about exploring the benefits and risks of a procedure called vitrectomy for people with diabetic retinopathy, a condition that affects the eyes. Diabetic retinopathy can cause bleeding in the eye and lead to vision loss. The study aims to find out if performing vitrectomy early can improve vision or if it might lead to more serious complications than the usual care. The study is important because it could help doctors understand the best way to treat this condition and potentially improve care for people with diabetic retinopathy. The study involves two parts. In the first part, people who have severe vision loss due to bleeding in the eye are randomly assigned to either get an early vitrectomy or follow the usual care. If the bleeding doesn't clear up after a year or if the retina starts to detach, then a vitrectomy is performed. In the second part, people with severe fibrovascular proliferations but still have useful vision are also randomly assigned to either get an early vitrectomy or follow the usual care. The usual care includes a treatment called photocoagulation, and a vitrectomy is performed if there's severe bleeding that doesn't clear up within 6 months or if the retina starts to detach. All participants are checked every 6 months for 2 years and then once a year to see how their vision changes.

Official TitleDiabetic Retinopathy Vitrectomy Study (DRVS)
Principal SponsorNational Eye Institute (NEI)
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 70 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Cardiovascular DiseasesDiabetes MellitusDiabetic AngiopathiesDiabetic RetinopathyEndocrine System DiseasesEye DiseasesEye HemorrhageHemorrhagePathologic ProcessesRetinal DetachmentRetinal DiseasesPathological Conditions, Signs and SymptomsVascular DiseasesVitreous HemorrhageDiabetes Complications

Criteria

Men and women eligible for the vitreous hemorrhage group had at least one eye with recent severe vitreous hemorrhage (within 5 months) and visual acuity of 5/200 or less. Patients eligible for the "very severe proliferative retinopathy with useful vision" group had extensive active fibrovascular proliferations and visual acuity of 10/200 or better.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has no location dataSave this study to your profile to know when the location data is available.
CompletedNo study centers
Early Vitrectomy vs. Conventional Management in Severe Diabetic Retinopathy | PatLynk